ViralClear, formed in March 2020 to obtain a drug whose potential use against COVID-19 already has substantial support in evidence. The company is employing considerable industry expertise to move it into clinical development.

Spring Bank Pharmaceuticals is continuing clinical programs during the COVID-19 challenge and advancing novel approaches to cancer, inflammation, and viruses.

Challenge breeds creativity, and a fresh example of that has emerged in Germany’s Ruhr Valley, with the company Abalos Therapeutics and the unique funding model that supported its launch.

Argenx is developing new antibody therapeutics for immunological diseases in the neuromuscular, hematology, oncology, and other areas. The company has a full pipeline of candidates and indications.

This 10-person startup in San Diego is aiming for muscle-spasm relief without sedation in a purified drug.

Started in 2017, Eikonizo Therapeutics has led an uphill battle to getting funding for its pipeline that includes drugs for ALS and Alzheimer’s, among other neurodegenerative diseases.

This unlikely CEO’s experience offers some valuable lessons in founding and scaling up a biotech company, particularly one in a nascent space such as regenerative medicine.

Adaptive Phage Therapeutics has created a large catalog of bacteria-killing viruses combined with a diagnostic test to identify and target specific bacterial strains infecting individual patients.

“The other part of being a CEO of a listed company is all about investors, and that was an uphill learning curve for me because I’d never dealt with that aspect,” explains Imugene’s CEO Leslie Chong.

In developing a new drug for MPN diseases, Imago is entering a space where two potential competitors, Jakafi and Inrebic, both JAK (janus associated kinase) inhibitors, are already on the market.

Scynexis is creating multiple development programs and a new class of antifungals — all in a single, and singular, drug.

With input from two long-time observers of the biopharma industry and its U.S. regulator, this article covers a cross-section of opinions regarding trends and proposals for improving the FDA review process.

What can make a company decide to enter new therapeutic entities into clinical development after decades as a dedicated supplier to bio research labs? Here we explain the reasons and implications of ArunA Bio’s decision.

Pluristem offers one example of how a new company in drug development can build the needed infrastructure to maintain its independence as a sponsor.